ATE320446T1 - Pluripotenzdeterminierender faktor und deren anwendung - Google Patents

Pluripotenzdeterminierender faktor und deren anwendung

Info

Publication number
ATE320446T1
ATE320446T1 AT03734758T AT03734758T ATE320446T1 AT E320446 T1 ATE320446 T1 AT E320446T1 AT 03734758 T AT03734758 T AT 03734758T AT 03734758 T AT03734758 T AT 03734758T AT E320446 T1 ATE320446 T1 AT E320446T1
Authority
AT
Austria
Prior art keywords
pluripotency
maintain
factors
application
confer
Prior art date
Application number
AT03734758T
Other languages
English (en)
Inventor
Ian Chambers
Austin Gerard Smith
Original Assignee
Univ Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Edinburgh filed Critical Univ Edinburgh
Application granted granted Critical
Publication of ATE320446T1 publication Critical patent/ATE320446T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AT03734758T 2002-01-30 2003-01-30 Pluripotenzdeterminierender faktor und deren anwendung ATE320446T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202149.1A GB0202149D0 (en) 2002-01-30 2002-01-30 Pluripotency determining factors and uses thereof

Publications (1)

Publication Number Publication Date
ATE320446T1 true ATE320446T1 (de) 2006-04-15

Family

ID=9930054

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03734758T ATE320446T1 (de) 2002-01-30 2003-01-30 Pluripotenzdeterminierender faktor und deren anwendung
AT06005029T ATE393167T1 (de) 2002-01-30 2003-01-30 Pluripotenzdeterminierende faktoren und deren anwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06005029T ATE393167T1 (de) 2002-01-30 2003-01-30 Pluripotenzdeterminierende faktoren und deren anwendung

Country Status (11)

Country Link
US (2) US7687266B2 (de)
EP (2) EP1470155B1 (de)
JP (1) JP2005536183A (de)
KR (1) KR20040093699A (de)
CN (1) CN1646562A (de)
AT (2) ATE320446T1 (de)
DE (2) DE60304037T2 (de)
DK (2) DK1470155T3 (de)
ES (1) ES2308616T3 (de)
GB (1) GB0202149D0 (de)
WO (1) WO2003064463A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4268169B2 (ja) * 2003-01-31 2009-05-27 伸弥 山中 胚性幹細胞の自己複製決定因子
US20060288431A1 (en) * 2003-02-13 2006-12-21 Norio Nakatsuji Marker for undifferentiated state of cell and composition and method for separation and preparation of stem cells
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) * 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
EP1802744A4 (de) * 2004-09-03 2008-06-18 Agency Science Tech & Res Verfahren zur erhaltung der pluripotenz von stamm-/vorläuferzellen
US8192988B2 (en) 2004-10-22 2012-06-05 University Of Central Florida Research Foundation, Inc. Methods for increasing potency of adult mesenchymal stem cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8759090B2 (en) * 2006-10-30 2014-06-24 University Of Central Florida Research Foundation, Inc. Stem cell banking system
GB0701062D0 (en) * 2007-01-19 2007-02-28 Evocell Ltd Biological materials and uses thereof
CN101743306A (zh) 2007-03-23 2010-06-16 威斯康星校友研究基金会 体细胞重编程
MX348010B (es) 2007-04-07 2017-05-23 Whitehead Inst Biomedical Res Reprogramacion de celulas somaticas.
WO2009032456A2 (en) * 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
ES2587395T3 (es) 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
ES2644588T3 (es) 2008-06-13 2017-11-29 Whitehead Institute For Biomedical Research Programación y reprogramación de células
WO2010019569A1 (en) 2008-08-12 2010-02-18 Cellular Dynamics International. Inc. Methods for the production of ips cells
WO2011094538A1 (en) * 2010-01-29 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Depletion of teratoma-forming pluripotent stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
DK3260140T3 (da) 2011-12-05 2021-04-19 Factor Bioscience Inc Fremgangsmåder og produkter til transficering af celler
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
EP2861238A4 (de) 2012-06-05 2016-03-16 Capricor Inc Optimierte verfahren zur erzeugung von herzstammzellen aus herzgewebe und deren verwendung in der herztherapie
EP2882445B1 (de) 2012-08-13 2019-04-24 Cedars-Sinai Medical Center Exosomen und mikroribonukleinsäuren zur geweberegeneration
RU2711249C2 (ru) 2012-11-01 2020-01-15 Фэктор Байосайенс Инк. Способы и продукты для экспрессии белков в клетках
CN103609526B (zh) * 2013-10-16 2015-10-07 中国科学院生物物理研究所 线粒体蛋白质翻译因子Guf1在雄性不育研究中的应用
KR20220100078A (ko) 2014-01-31 2022-07-14 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
AU2018255346B2 (en) 2017-04-19 2024-05-02 Capricor Inc Methods and compositions for treating skeletal muscular dystrophy
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022693A1 (en) 1995-01-24 1996-08-01 The Board Of Regents Of The University Of Texas System Self-renewing pluripotent hematopoietic stem cell compositions, methods of use, and culture systems therefor
WO1997030151A1 (en) 1996-02-16 1997-08-21 The University Of Edinburgh Cytokine expressed by dia/lif-deficient embryonic stem cells for the inhibition of differentiation
US6159950A (en) * 1998-10-16 2000-12-12 Cornell Research Foundation, Inc. Method of modulating hair growth
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2002310222A1 (en) * 2001-05-31 2002-12-09 Chiron Corporation P-cadherin as a target for anti-cancer therapy

Also Published As

Publication number Publication date
DE60320599D1 (de) 2008-06-05
DK1470155T3 (da) 2006-07-24
DE60320599T2 (de) 2009-10-29
EP1470155B1 (de) 2006-03-15
CN1646562A (zh) 2005-07-27
KR20040093699A (ko) 2004-11-08
DE60304037D1 (de) 2006-05-11
DE60304037T2 (de) 2006-11-09
EP1698639B1 (de) 2008-04-23
ATE393167T1 (de) 2008-05-15
GB0202149D0 (en) 2002-03-20
WO2003064463A3 (en) 2003-12-11
EP1470155A2 (de) 2004-10-27
EP1698639A2 (de) 2006-09-06
JP2005536183A (ja) 2005-12-02
ES2308616T3 (es) 2008-12-01
US20050255573A1 (en) 2005-11-17
US20100144039A1 (en) 2010-06-10
WO2003064463B1 (en) 2004-02-12
EP1698639A3 (de) 2006-12-06
US7687266B2 (en) 2010-03-30
WO2003064463A2 (en) 2003-08-07
DK1698639T3 (da) 2008-07-14

Similar Documents

Publication Publication Date Title
ATE320446T1 (de) Pluripotenzdeterminierender faktor und deren anwendung
ATE514772T1 (de) Multipotente erwachsene stammzellen und verfahren zu deren isolierung
BR0308919A (pt) Células-tronco programáveis, desdiferenciadas de origem monocìtica, e sua produção e uso
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
MXPA04000982A (es) Metodos para movilizar celulas progenitoras/madre.
ATE439429T1 (de) Multipotente neurale stammzellen aus hautgewebe und deren verwendungen
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
MY145117A (en) Disposable diaper
DE60210623D1 (de) Ex-vivo isolierte cd25+cd4+ t zellen mit immunsuppressiver aktivität und deren anwendungen
ATE508150T1 (de) Bei raumtemperatur lanzettierbare silikonhydrogele
DK1682491T3 (da) Usymmetrisk geleringsmiddel
BRPI0620291B8 (pt) método e uso de 4,4'-diaminodifenil sulfona para produzir cepas rugosas de bactérias e composição de modulador imune
BRPI0605942A (pt) composição cosmética para o tratamento de fibras de queratina, dispositivo em aerossol, processo de tratamento cosmético, e, uso de uma composição cosmética
WO2006094550A8 (de) Verwendung kosmetischer zubereitungen mit einem gehalt an nicht molekular gebundenem freien sauerstoff
BR0110999B1 (pt) "dispersões de pur aquosas, modificadas por sol de sìlica, bem como sua aplicação".
ATE390059T1 (de) Vorrichtung, zum aufbewahren und auftragen bestehend aus einem aus partikeln bestehenden körper
DE60313580D1 (de) Persönliches pflegeprodukt
ATE363890T1 (de) Kationische polymerisate und deren verwendung in kosmetischen formulierungen
ATE434940T1 (de) Verfahren zur verbesserung der immunfunktion bei säugern unter verwendung von lactobacillus reuteri-stämmen
DE60314219D1 (de) Verwendung von Adenosin oder einem Adenosinanalogen zur Glättung von feinen Linien
BR112012014730A2 (pt) "método cosmético para tratar odores corporais usando uma composição com base em bacteriocina"
CA105215S (en) Packaging with cosmetic composition
ATE372354T1 (de) Pulverbeschichtungsmittel und deren verwendung in pulverbeschichtungsverfahren
ATE340253T1 (de) Zellkonstrukte erhältlich aus mesenchymalen stammzellen und davon ableitbaren zellen und ihre verwendung
WO2007005787A3 (en) Methods and compositions for keratinocyte culture and therapeutics

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties